Prestige Consumer Healthcare Stock Hits New 52-Week Low at $59.62

Prestige Consumer Healthcare, Inc. has reached a new 52-week low, trading at USD 59.62 as of October 31, 2025. This marks a significant decline for the small-cap company, which operates within the Pharmaceuticals & Biotechnology sector. Over the past year, Prestige Consumer has experienced a performance drop of 7.75%, contrasting sharply with the S&P 500's gain of 19.89%.
The company's financial metrics reveal a mixed picture. With a market capitalization of USD 3,511 million, Prestige has a price-to-earnings (P/E) ratio of 20.00. However, it has not offered dividends, and its debt-to-equity ratio stands at 0.46. The return on equity is reported at 11.94%, while the price-to-book ratio is 1.89.

Recent quarterly results have shown net sales at USD 249.53 million and operating profit at USD 79.42 million, both reflecting the lowest figures in recent times. Despite a modest annual growth rate of 3.13% in net sales over the last five years, the stock's performance has been below par, with a return of -12.91% in the past year. High institutional holdings at 100% indicate a strong presence of institutional investors, who typically have the resources to analyze company fundamentals effectively.